Evidence map›Paper›PMID 32053994›Full record

ArticleInternational journal of molecular sciences2020

Tissue Distribution and Receptor Activation by Somapacitan, a Long Acting Growth Hormone Derivative.

Maj Petersen, Prafull S Gandhi, Jens Buchardt, Tomas Alanentalo, Johannes Josef Fels, Nils Langeland Johansen, Peter Helding-Kvist, Knud Vad, Peter Thygesen

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Maj PetersenGlobal Drug Discovery, Novo Nordisk A/S, 2760 Måløv, Denmark.
Prafull S GandhiGlobal Research Technologies, Novo Nordisk A/S, 2760 Måløv, Denmark.
Jens BuchardtGlobal Research Technologies, Novo Nordisk A/S, 2760 Måløv, Denmark.
Tomas AlanentaloUmeå Centre for Molecular Medicine, Umeå University, 90187 Umeå, Sweden.
Johannes Josef FelsGlobal Research Technologies, Novo Nordisk A/S, 2760 Måløv, Denmark.
Nils Langeland JohansenGlobal Research Technologies, Novo Nordisk A/S, 2760 Måløv, Denmark.
Peter Helding-KvistGlobal Drug Discovery, Novo Nordisk A/S, 2760 Måløv, Denmark.
Knud VadGlobal Development, Novo Nordisk A/S, 2860 Søborg, Denmark.
Peter ThygesenGlobal Drug Discovery, Novo Nordisk A/S, 2760 Måløv, Denmark.
Novo Nordisk (Denmark) · DKUmeå University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Somapacitan is a long-acting, once-weekly, albumin-binding growth hormone (GH) derivative. The reversible albumin-binding properties leads to prolonged circulation half-life. Here, we investigated and compared somapacitan with human GH on downstream receptor signaling in primary hepatocytes and hepatocellular models and using isothermal titration calorimetry to characterize receptor binding of somapacitan in the presence or absence of human serum albumin (HSA). With non-invasive fluorescence imaging we quantitatively visualize and compare the temporal distribution and examine the tissue-specific growth hormone receptor (GHR) activation at distribution sites. We found that signaling kinetics were slightly more rapid and intense for GH compared with somapacitan. Receptor binding isotherms were characterized by a high and a low affinity interaction site with or without HSA. Using in vivo optical imaging we found prolonged systemically biodistribution of somapacitan compared with GH, which correlated with plasma pharmacokinetics. Ex vivo mouse organ analysis revealed that the temporal fluorescent intensity in livers dosed with somapacitan was significantly increased compared with GH-dosed livers and correlated with the degree of downstream GHR activation. Finally, we show that fluorescent-labeled analogs distributed to the hypertrophic zone in the epiphysis of proximal tibia of hypophysectomized rats and that somapacitan and GH activate the GHR signaling in epiphyseal tissues.

Indexed as

AnimalsCells, CulturedFemaleHepatocytesHuman Growth HormoneHumansMaleMiceMice, NudeModels, MolecularRats, Sprague-DawleyReceptors, SomatotropinTissue DistributionHuman Growth HormoneReceptors, Somatotropinbiodistributionfluorescence molecular tomographyhuman growth hormonelight-sheet fluorescence microscopyproximal epiphysisP-STAT5 activationreceptor signalingsomapacitan

Identifiers

PMID32053994
PMCPMC7072805
OpenAlexW3005883867

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.